MGrx - A Novel Multi-modal Thermal Device for Treating Moderate to Severe Meibomian Gland Dysfunction and Dry Eye

Brittany J. McMurren1, Michael A. Kling2, Andrew Fasciani3, M. Henrietta Nymark-McMahon4, *
1 O.D., Werner Optometry, El Cajon, CA
2 O.D., Invision Optometry, San Diego, CA
3 O.D., 4S Eyecare & Optometry, 4S Ranch, CA
4 Consultant to OcuSci, Inc., 15043 Paso Del Sol, Del Mar, CA 92014, CA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 437
Abstract HTML Views: 165
PDF Downloads: 145
ePub Downloads: 119
Total Views/Downloads: 866
Unique Statistics:

Full-Text HTML Views: 257
Abstract HTML Views: 112
PDF Downloads: 102
ePub Downloads: 81
Total Views/Downloads: 552

Creative Commons License
© 2023 McMurren et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Consultant to OcuSci, Inc., 15043 Paso Del Sol, Del Mar, CA 92014, CA; Tel: (888) 809-6424; Fax: (888) 809-6424; E-mail:



MGD (meibomian gland dysfunction) is a chronic cause of dry eyes. Thermal expression of the meibomian glands, along with massage and debridement, is an effective treatment for MGD.


We describe a multi-modal thermal device (MGrx) to manage meibomian gland dysfunction (MGD). We observed the efficacy and safety of the MGrx to manage MGD in one 15-minute in-office session.


We enrolled 37 patients in a prospective, open-label trial of the novel MGrx. Patients were enrolled with a Standard Patient Evaluation for Eye Dryness (SPEED) score > 12 or a Tear Breakup Time (TBUT) of < 6 seconds in at least one eye. After screening for eligibility, one 15-minute MGrx treatment was provided to each patient. The patient assessment consisted of a SPEED score, TBUT, and a Meibomian gland score (MGS) obtained pre-treatment and at a follow-up visit 30 days after the treatment.


Dry eye symptoms improved in the patient population, as measured by SPEED score, MGS, and TBUT, by 40%, 341%, and 145%, respectively (p<0.05). No adverse reactions were noted among the patients.


A single 15-minute MGrx treatment was effective at significantly improving dry eye symptoms secondary to MGD in adult patients, as measured by SPEED score. Additionally, a single MGrx treatment improved meibomian gland function and all measures of MGD in the adult patients treated. Given the relatively low risk and efficient delivery of the MGrx treatment, a single MGrx treatment should be considered as a first-line treatment for MGD.

Keywords: Dry eye, Meibomian gland dysfunction, Thermal device, Thermal pulsation, MGrx, MGD, MGS, IPL, TBUT, SPEED, OcuSci, LipiFlow, MiBoFlo, TearCare, iLux, Systane.